A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus |
Bang, Sun-Hwi
(East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University)
Yoon, Jeung-Won (East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University) Cho, Chong-Kwan (East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University) Shin, Ji-Eun (Department of Statistics, Chungnam National University) Lee, Yeon-Weol (East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University) Yoo, Hwa-Seung (East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University) |
1 | Noble J, Ellis PM, Mackay JA, Evans WK. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol. 2006;1(9):1042-58. DOI |
2 | Hotta K, Fujiwara Y, Kiura K, Takigawa N, Tabata M, Ueoka H, et al. Relationship between response and survival in more than 50,000 patients with advanced non-smallcell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol. 2007;2(5):402-7. DOI |
3 | Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist. 2008;13(Suppl1):28-36 DOI ScienceOn |
4 | Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55. DOI ScienceOn |
5 | Gill S, Sargent D. Endpoints for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate endpoint for overall survival? Oncologist. 2006;11(6):624-9. DOI ScienceOn |
6 | Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. [cited 2012 January 20]. Available from: http://ctep.cancer.gov. |
7 | Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22(2):330-53. |
8 | Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J. 2009;15(5):401-5. DOI ScienceOn |
9 | Mandrekar SJ, Qi YW, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM Jr, et al. Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(1):3-9. DOI ScienceOn |
10 | Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-103. |
11 | Yoo HS, Choi WJ, Cho JH, Lee YY, Seo SH, Lee YW, et al. The clinical study in 105 cases for stomach cancer patients on the effects by Hangamdan. Hyehwa Med. 2000;9(2):7-25. |
12 | Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-8. DOI ScienceOn |
13 | Socinski MA. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am. 2003;9(2):207-36. DOI ScienceOn |
14 | Choi BL, Son CK. The clinical study in 62 cases for lung cancer patients on the effects by Hangamdan. Collect Dissert Daejeon University. 2001;10(1):121-31. |
15 | Lee YY, Seo SH, Yoo HS, Choi WJ, Cho JH, Lee YW, et al. The clinical study in 83 cases for colorectal cancer patients on the effects by Hangamdan. J of Kor Oriental Oncology. 2000;6(1):165-80. |
16 | Han SS, Cho CK, Lee YW, Yoo HS. A case report on extranodal marginal zone B cells of mucosa-associated lymphoid tissue (MALT) type lymphoma treated with HangAmDan. Korean J Orient Int Med. 2008;29(3):810-8. |
17 | Bang SH, Lee JH, Cho JH, Lee YW, Son CG, Cho CK, et al. A case report of pancreatic cancer treated with lymph node metastasis. Korean J Orient Int Med. 2007;28(4):978-85. |
18 | Bang JY, Kim EY, Shim TK, Yoo HS, Lee YW, Kim YS, et al. Analysis of anti-angiogenic mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine, using antibody microarray chip. BioChip J. 2010;4(4):350-5. DOI |
19 | Choi YJ, Shin DY, Lee YW, Cho CK, Kim GY, Kim WJ, et al. Inhibition of cell motility and invasion by HangAmDan-B in NCI-H460 human non-small cell lung cancer cells. Oncol Rep. 2011;26(6):1601-8. |
20 | Yoo SH, Yoo HS, Cho CK, Lee YW. A case report for recurred squamous cell lung carcinoma treated with Hang-Am-Dan: 7-year follow up. Korean J Orient Int Med. 2007;28(2):385-90. |
21 | Jeong TY, Park BK, Lee YW, Cho CK, Yoo HS. Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan. Chinese Journal of Lung Cancer. 2010;13(11):1009-15. |
22 | Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. DOI ScienceOn |
23 | World Health Organization. The global burden of disease: 2004 Update. Geneva: World Health Organization; 2008. p.12-3. |
24 | Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917. DOI ScienceOn |
25 | Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. DOI ScienceOn |
26 | Govindan R. The Washington manual of oncology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p.134-42. |
27 | Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(Suppl 1):5-13. DOI ScienceOn |
28 | Cancer Care. Types of lung cancer. [cited 2012 January 20]. Available from: http://www.lungcancer.org/reading/types.sphp. |
29 | Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10-30. DOI ScienceOn |
30 | Cho JH, Yoo HS, Lee YW, Son CK, Cho CK. Clinical study in 320 cases for cancer patients on the effect Hangamdan. Collect Dissert Daejeon University. 2004;12(2):157-75. |